LLY

1,015.5

+2.79%↑

JNJ

230.41

+2.69%↑

ABBV

208.54

+0.36%↑

UNH

400.53

+1.04%↑

AZN

187.75

+1.77%↑

LLY

1,015.5

+2.79%↑

JNJ

230.41

+2.69%↑

ABBV

208.54

+0.36%↑

UNH

400.53

+1.04%↑

AZN

187.75

+1.77%↑

LLY

1,015.5

+2.79%↑

JNJ

230.41

+2.69%↑

ABBV

208.54

+0.36%↑

UNH

400.53

+1.04%↑

AZN

187.75

+1.77%↑

LLY

1,015.5

+2.79%↑

JNJ

230.41

+2.69%↑

ABBV

208.54

+0.36%↑

UNH

400.53

+1.04%↑

AZN

187.75

+1.77%↑

LLY

1,015.5

+2.79%↑

JNJ

230.41

+2.69%↑

ABBV

208.54

+0.36%↑

UNH

400.53

+1.04%↑

AZN

187.75

+1.77%↑

Inicio・Lista de Acciones・Ironwood Pharmaceuticals Inc

Ironwood Pharmaceuticals Inc

Cerrado

SectorSanidad

3.65 -10.54

Comprar Vender

Resumen

Variación precio

24h

Actual

Mínimo

3.57

Máximo

4.07

Métricas clave
By Trading Economics
Ingresos	21M 61M
Ventas	-74M 48M
P/B Media del Sector	28.688 49.8
Margen de beneficios	128.703
Empleados	100
EBITDA	-68M 8.8M

Recomendaciones
By TipRanks
Recomendaciones	Comprar
Estimación a 12 Meses	+83.37% upside

Dividendos
By Dow Jones
Próximas Ganancias	6 ago 2026

Estadísticas de Mercado
By TradingEconomics
Capitalización Mercado	146M 756M
Apertura anterior	14.19
Cierre anterior	3.65

Noticias sobre sentimiento de mercado

By Acuity

50%

150 / 346 Clasificación en Healthcare

Puntuación técnica

By Trading Central

Confianza

Strong Bearish Evidence

N/A / 0.9337 Soporte y Resistencia

Ironwood Pharmaceuticals Inc Gráfico

Resultados pasados no son un indicador fiable de resultados futuros.

Noticias Relacionadas

12 may 2026, 22:50 UTC

Ganancias

Commonwealth Bank of Australia Increases Provisions as 3Q Profit Slips

12 may 2026, 22:49 UTC

Ganancias

Aristocrat Leisure Raises Midyear Dividend, Swells Share Buyback Program

12 may 2026, 22:32 UTC

Ganancias

JBS 1Q Profit Slides Amid Rising Cattle Costs -- Update

12 may 2026, 23:48 UTC

Charlas de Mercado

Nikkei May Decline Amid Uncertainty Over Iran Conflict -- Market Talk

12 may 2026, 22:57 UTC

Charlas de Mercado

Ganancias

JBS Says Consumers Are Looking to Pork for Affordable Protein -- Market Talk

12 may 2026, 22:26 UTC

Ganancias

Aristocrat Leisure to Increase On-Market Share Buyback by A$1 Billion

12 may 2026, 22:25 UTC

Ganancias

Aristocrat Leisure 1H Normalized Pretax Profit A$997.3 Million, Up 9.4% on Year

12 may 2026, 22:25 UTC

Ganancias

Aristocrat Leisure Interim Dividend A$0.50/Security

12 may 2026, 22:24 UTC

Ganancias

Aristocrat Leisure 1H Revenue From Continuing Operations A$3.03 Billion, Down 0.2% on Year

12 may 2026, 22:23 UTC

Ganancias

Aristocrat Leisure 1H Net Profit From Discontinued Operations A$7.0 Million

12 may 2026, 22:23 UTC

Ganancias

Aristocrat Leisure 1H Net Profit From Continuing Operations A$798.5 Million, Up 56%

12 may 2026, 22:19 UTC

Ganancias

CBA: Total Provision Coverage Ratio 1.57%>CBA.AU

12 may 2026, 22:14 UTC

Ganancias

CBA: Business Lending Continued to Grow Above System>CBA.AU

12 may 2026, 22:14 UTC

Ganancias

CBA Had 1.4M Business Transaction Accounts at March 31, Up 7% on Year>CBA.AU

12 may 2026, 22:13 UTC

Ganancias

CBA Household Deposits Grew A$38B in 12 Months Through March>CBA.AU

12 may 2026, 22:12 UTC

Ganancias

CBA Home Loan Balances Grew A$41B in 12 Months Through March>CBA.AU

12 may 2026, 22:12 UTC

Ganancias

CBA 3Q New Home Loan Funding A$45B>CBA.AU

12 may 2026, 22:11 UTC

Ganancias

Correct: JBS NV 1Q EPS 20c, Not 21c >JBS

12 may 2026, 22:11 UTC

Ganancias

CBA: CET1 Level 2 Capital Ratio 11.6%>CBA.AU

12 may 2026, 22:10 UTC

Ganancias

CBA: Customer Deposit Funding Ratio 79%>CBA.AU

12 may 2026, 22:09 UTC

Ganancias

CBA: Underlying Portfolio Credit Quality Remains Sound>CBA.AU

12 may 2026, 22:09 UTC

Ganancias

CBA: Higher Collective Provisions Reflect Geopolitical, Macroeconomic Uncertainty >CBA.AU

12 may 2026, 22:08 UTC

Ganancias

CBA 3Q Loan Impairment Expense A$316M>CBA.AU

12 may 2026, 22:07 UTC

Ganancias

CBA: Costs Up on Higher Cloud Computing Volumes, Software Licenses, AI Investment>CBA.AU

12 may 2026, 22:06 UTC

Ganancias

CBA 3Q Operating Expenses Up 1% Excluding Restructuring, Notable Items>CBA.AU

12 may 2026, 22:06 UTC

Ganancias

CBA: 3Q Underlying Net Interest Margin Was Broadly Stable>CBA.AU

12 may 2026, 22:05 UTC

Ganancias

CBA: Lending, Deposit Volume Growth Offset Impact of Two Fewer Days >CBA.AU

12 may 2026, 22:04 UTC

Ganancias

Commonwealth Bank: Operating Income Flat in March Quarter >CBA.AU

12 may 2026, 22:04 UTC

Ganancias

Commonwealth Bank 3Q Cash Profit Up 4% on Year>CBA.AU

12 may 2026, 22:04 UTC

Ganancias

Commonwealth Bank 3Q Cash Profit Down 1% on 1H Quarterly Average>CBA.AU

Comparación entre iguales

Cambio de precio

Ironwood Pharmaceuticals Inc previsión

Precio Objetivo

By TipRanks

83.37% repunte

Estimación a 12 Meses

Media 7.5 USD 83.37%

Máximo 10 USD

Mínimo 5 USD

De acuerdo con 3 analistas de Wall Street que ofrecen objetivos de precios a 12 meses para Ironwood Pharmaceuticals Inc Dist en los últimos 3 meses.

Consenso

By TipRanks

Comprar

3 ratings

Comprar

Mantener

Vender

De acuerdo con 3 analistas que ofrecen calificaciones bursátiles a para Ironwood Pharmaceuticals Inc Dist en los últimos 3 meses.

Puntuación técnica

By Trading Central

N/A / 0.9337Soporte y Resistencia

Recent bearish events outweigh bullish events.

There are no events.

All events are bearish.

Sentimiento

By Acuity

150 / 346 Clasificación en Sanidad

Finanzas

Gastos de venta y administración

Gastos operativos

Beneficio antes de impuestos

Ventas

Coste de ventas

Beneficio bruto de ventas

Gasto por intereses de deuda

EBITDA

Beneficio operativo

Acerca de Ironwood Pharmaceuticals Inc

Ironwood Pharmaceuticals, Inc., a healthcare company, focuses on the development and commercialization of gastrointestinal (GI) products. It markets linaclotide, a guanylate cyclase type-C (GC-C) agonist for the treatment of adults suffering from irritable bowel syndrome with constipation or chronic idiopathic constipation under the LINZESS name in the United States, Mexico, Japan, Saudi Arabia, and China, as well as under the CONSTELLA name in the Canada and European countries. The company is also developing IW-3300, a GC-C agonist for the treatment of visceral pain conditions, including interstitial cystitis/bladder pain syndrome and endometriosis; Apraglutide, a next-generation, long-acting synthetic peptide analog of glucagon-like peptide-2, as a differentiated therapeutic for rare diseases, including short bowel syndrome dependent on parenteral support and acute graft versus host disease; and CNP-104, an immune nanoparticle for the treatment of primary biliary cholangitis. The company has strategic partnerships with AbbVie Inc., AstraZeneca AB, and Astellas Pharma Inc. for the development and commercialization of linaclotide. The company was formerly known as Microbia, Inc. and changed its name to Ironwood Pharmaceuticals, Inc. in April 2008. Ironwood Pharmaceuticals, Inc. was incorporated in 1998 and is headquartered in Boston, Massachusetts.